Clinical trials: SARS-COv2 Related Interstitial Pneumonia
Respiratory Failure, Sars-CoV-2
The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial
In recent months, more and more studies suggest tele-rehabilitation as a means to be exploited to reduce the risk of contagion. The intent of our study is to verify the effectiveness of a tele-rehabilitation intervention through…
- Conditions
- Respiratory Failure, Sars-CoV-2, Covid19, ARDS
- Trial name
- NCT05007457
- Testing
- Telerehabilitation
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
SARS-COv2 Related Interstitial Pneumonia
TOFAcitinib in SARS-CoV2 Pneumonia
Immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to SARS-CoV2 infection. Tofacitinib, a JAK1/3-Inhibitor, could mitigate alveolar inflammation by blocking IL-6 signal.
- Trial name
- NCT04332042
- Testing
- Tofacitinib
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Università Politecnica delle Marche